A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Clinical trial NCT02365662 · TERMINATED

Trial details

NCT number: NCT02365662
Sponsor: AbbVie
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma Non-small Cell Lung Cancer Triple Negative Breast Cancer Colorectal Carcinoma Glioblastoma Multiforme

Start date: 2015-01-09
Primary completion: 2018-03-15
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.